Neutrophil‐to‐Lymphocyte Ratio and Early Neurological Deterioration in Stroke Patients: A Systematic Review and Meta‐Analysis
Shirin Sarejloo, Hadis Kheradjoo, Sarvin Es haghi, Samaneh Hosseini, Morad Kohandel Gargari, Amir Azarhomayoun, Shokoufeh Khanzadeh, Shahram Sadeghvand
Abstract
In light of the growing emphasis on classifying stroke patients for different levels of monitoring intensity and emergency treatments, we conducted a systematic review of a wide range of clinical studies, according to the preferred reporting items for systematic review and meta‐analysis (PRISMA) guidelines, with no restrictions on the language or publication date, to analyze the potential of the neutrophil‐to‐lymphocyte ratio (NLR) as an early neurological deterioration (END) risk predictor. A comprehensive search was carried out in PubMed, Scopus, and Web of Science databases from the inception to March 13, 2022. Nine articles were included in our study. Stroke patients with END had significantly higher NLR levels than the those without END (SMD = 0.73; CI 95 % = 0.42‐1.05, P value < 0.001). In the subgroup analysis, according to ethnicity, East Asian patients with END had elevated levels of NLR compared to those without END (SMD = 0.79; CI 95 % = 0.52‐1.06, P value < 0.001). However, the difference in the Caucasian group was not significant (SMD = 0.60; CI 95 % = −0.50‐1.70, P value = 0.28). In the subgroup analysis according to the type of stroke, the NLR levels in patients with hemorrhagic stroke who developed END were similar to those without END (SMD = 0.84, CI 95 % = −0.10‐1.77, P value = 0.07). Vice versa, in the ischemic stroke group, patients with END had elevated levels of NLR compared to those without END (SMD = 0.67, CI 95 % = 0.38‐0.96, P value < 0.001). NLR is a unique inflammatory biomarker whose increase in END suggests an immune system dysfunction in the pathogenesis of the disease.